Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

10.1093/annonc/mdy550

Saved in:

Bibliographic Details
Main Authors:	Sundar, R, Huang, KK, Qamra, A, Kim, K-M, Kim, ST, Kang, WK, Tan, ALK, Lee, J, Tan, P
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	OXFORD UNIV PRESS 2019
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology epigenetic alternate promoter immune checkpoint inhibition pembrolizumab immunotherapy gastric cancer TUMORS
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/155022
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-155022
record_format	dspace
spelling	sg-nus-scholar.10635-1550222024-04-04T01:06:19Z Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer Sundar, R Huang, KK Qamra, A Kim, K-M Kim, ST Kang, WK Tan, ALK Lee, J Tan, P DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) LIFE SCIENCES INSTITUTE PHYSIOLOGY Science & Technology Life Sciences & Biomedicine Oncology epigenetic alternate promoter immune checkpoint inhibition pembrolizumab immunotherapy gastric cancer TUMORS 10.1093/annonc/mdy550 ANNALS OF ONCOLOGY 30 3 424-430 2019-06-03T04:22:05Z 2019-06-03T04:22:05Z 2019-03-01 2019-06-03T00:57:26Z Article Sundar, R, Huang, KK, Qamra, A, Kim, K-M, Kim, ST, Kang, WK, Tan, ALK, Lee, J, Tan, P (2019-03-01). Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. ANNALS OF ONCOLOGY 30 (3) : 424-430. ScholarBank@NUS Repository. https://doi.org/10.1093/annonc/mdy550 0923-7534 1569-8041 https://scholarbank.nus.edu.sg/handle/10635/155022 en OXFORD UNIV PRESS Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology epigenetic alternate promoter immune checkpoint inhibition pembrolizumab immunotherapy gastric cancer TUMORS
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology epigenetic alternate promoter immune checkpoint inhibition pembrolizumab immunotherapy gastric cancer TUMORS Sundar, R Huang, KK Qamra, A Kim, K-M Kim, ST Kang, WK Tan, ALK Lee, J Tan, P Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
description	10.1093/annonc/mdy550
author2	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
author_facet	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) Sundar, R Huang, KK Qamra, A Kim, K-M Kim, ST Kang, WK Tan, ALK Lee, J Tan, P
format	Article
author	Sundar, R Huang, KK Qamra, A Kim, K-M Kim, ST Kang, WK Tan, ALK Lee, J Tan, P
author_sort	Sundar, R
title	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
title_short	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
title_full	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
title_fullStr	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
title_full_unstemmed	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
title_sort	epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
publisher	OXFORD UNIV PRESS
publishDate	2019
url	https://scholarbank.nus.edu.sg/handle/10635/155022
_version_	1795373942438887424

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

Similar Items